First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

被引：0
作者：
Tianhong Li
Patricia LoRusso
Michael L. Maitland
Sai-Hong Ignatius Ou
Erkut Bahceci
Howard A. Ball
Jung Wook Park
Geoffrey Yuen
Anthony Tolcher
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology
[2] Wayne State University,Karmanos Cancer Institute
[3] University of Chicago Medicine,Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics
[4] University of California Irvine School of Medicine,Chao Family Comprehensive Cancer Center
[5] Astellas Pharma Global Development,undefined
[6] South Texas Accelerated Research Therapies (START) Center for Cancer Care,undefined
[7] Present address: Yale Smilow Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
ASP3026; Neoplasms; ALK inhibitor; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[31]   Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors [J].
Sun, Yongkun ;
Yang, Lin ;
Hao, Xuezhi ;
Liu, Yutao ;
Zhang, Jinwen ;
Ning, Zhiqiang ;
Shi, Yuankai .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
[32]   A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors [J].
Hong, David S. ;
Rosen, Peter ;
Lockhart, A. Craig ;
Fu, Siqing ;
Janku, Filip ;
Kurzrock, Razelle ;
Khan, Rabia ;
Amore, Benny ;
Caudillo, Isaac ;
Deng, Hongjie ;
Hwang, Yuying C. ;
Loberg, Robert ;
Ngarmchamnanrith, Gataree ;
Beaupre, Darrin M. ;
Lee, Peter .
ONCOTARGET, 2015, 6 (21) :18693-18706
[33]   A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma [J].
Hollebecque, A. ;
Deutsch, E. ;
Massard, C. ;
Gomez-Roca, C. ;
Bahleda, R. ;
Ribrag, V. ;
Bourgier, C. ;
Lazar, V. ;
Lacroix, L. ;
Gazzah, A. ;
Varga, A. ;
de Baere, T. ;
Beier, F. ;
Kroesser, S. ;
Trang, K. ;
Zenke, F. T. ;
Klevesath, M. ;
Soria, Jean-Charles .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) :1530-1538
[34]   Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors [J].
Yongkun Sun ;
Lin Yang ;
Xuezhi Hao ;
Yutao Liu ;
Jinwen Zhang ;
Zhiqiang Ning ;
Yuankai Shi .
Journal of Hematology & Oncology, 12
[35]   A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma [J].
A. Hollebecque ;
E. Deutsch ;
C. Massard ;
C. Gomez-Roca ;
R. Bahleda ;
V. Ribrag ;
C. Bourgier ;
V. Lazar ;
L. Lacroix ;
A. Gazzah ;
A. Varga ;
T. de Baere ;
F. Beier ;
S. Kroesser ;
K. Trang ;
F. T. Zenke ;
M. Klevesath ;
Jean-Charles Soria .
Investigational New Drugs, 2013, 31 :1530-1538
[36]   Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors [J].
Edward Sausville ;
Patricia LoRusso ;
Michael Carducci ;
Judith Carter ;
Mary F. Quinn ;
Lisa Malburg ;
Nilofer Azad ;
David Cosgrove ;
Richard Knight ;
Peter Barker ;
Sonya Zabludoff ;
Felix Agbo ;
Patricia Oakes ;
Adrian Senderowicz .
Cancer Chemotherapy and Pharmacology, 2014, 73 :539-549
[37]   Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors [J].
Sausville, Edward ;
LoRusso, Patricia ;
Carducci, Michael ;
Carter, Judith ;
Quinn, Mary F. ;
Malburg, Lisa ;
Azad, Nilofer ;
Cosgrove, David ;
Knight, Richard ;
Barker, Peter ;
Zabludoff, Sonya ;
Agbo, Felix ;
Oakes, Patricia ;
Senderowicz, Adrian .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) :539-549
[38]   Two First-in-Human, Open-Label, Phase I Dose-Escalation Safety Trials of MEDI-528, a Monoclonal Antibody Against Interleukin-9, in Healthy Adult Volunteers [J].
White, Barbara ;
Leon, Francisco ;
White, Wendy ;
Robbie, Gabriel .
CLINICAL THERAPEUTICS, 2009, 31 (04) :728-740
[39]   First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors [J].
Kim, Sung-Bae ;
Bae, Kyun-Seop ;
Lee, Jae Lyun ;
Lee, Won Sik ;
Ock, Chan-Young ;
Lee, Myong-Jae ;
Bang, Jeongsook ;
Hong, Min Ju ;
Roh, Eun-Jihn ;
Ha, Kyoung Soo ;
Lim, Jong-Ha ;
Kim, Yong-Man .
CANCER MEDICINE, 2025, 14 (04)
[40]   A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors [J].
Gun Min Kim ;
Tony Reid ;
Sang Joon Shin ;
Sun Young Rha ;
Joong Bae Ahn ;
Sung Sil Lee ;
Hyun Cheol Chung .
Investigational New Drugs, 2017, 35 :773-781
12345